ChemGenex's Phantom Expanded Access Program For Omapro Cited By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
DDMAC says that there is no expanded access program for the unapproved leukemia drug Omapro (omacetaxine mepesuccinate), but even if there were one, ChemGenex would not be allowed to promote it.
You may also be interested in...
Regeneron Pushes Legal, Ethical Boundaries With Offer Of COVID-19 Antibody To Biden Campaign
Company may have violated FDA’s preapproval promotion restrictions by discussing compassionate use option with Joe Biden’s team and by publicizing it on TV, highlighting the fine line between making the general public aware of expanded access and touting an investigational product as useful for a particular illness.
IND Promotion Quandary Again Trips Up Burzynski Research Institute
The institute has come under scrutiny in the past for how it describes its investigational cancer products, but more mainstream oncology companies have also been cited for jumping the gun with promotional claims for products FDA hasn’t yet approved.
Cancer Drug Website Draws FDA's Ire For Promoting A Product In Clinical Trials
Keryx Biopharmaceuticals is cited for claiming on its website that its investigational oncology drug perifosine is safe and effective.